BioWorld

Feb. 18, 2005

Dendreon Shows Survival Benefit In Phase III Study Of Provenge

A month after reporting a miss in a Phase III trial of its prostate cancer drug Provenge, Dendreon Corp. rebounded with data from the study showing a statistical improvement in patient survival rate. (BioWorld Today) Read More

FDA Doctor Questions Need For Any Drugs From the COX-2 Class

'Matchmaker' SNP Study Paves Way For Pharmacogenomics

BioCryst Raises $23.9M Privately To Fund Lead Clinical Products

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...